In February, we added 116 citations in DIDB, including 59 in vitro (with 21 articles published in February 2025) and 57 in vivo articles (with 44 articles published in February 2025).
4 NDA/BLAs approved in 2024, including concizumab (ALHEMO), ensifentrine (OHTUVAYRE), marstacimab (HYMPAVZI), vanzacaftor and tezacaftor and deutivacaftor (ALYFTREK), and 1 NDA approved in 2025, namely treosulfan (GRAFAPEX), were also curated in DIDB.
You can check the citations that are recently published and entered in DIDB and all the NDAs/BLAs in DIDB.
As always, feel free to contact us if you have any questions or comments.